Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study

Main Article Content

Sonja Ständer
University Hospital Münster Department of Dermatology

Elke Weisshaar
Ruprecht-Karls University

Jennifer L Parish
Sidney Kimmel Medical College at Thomas Jefferson University Department of Dermatology and Cutaneous Biology

Jacek C Szepietowski
Wroclaw Medical University

Adam Reich
University of Rzeszow

Neil J Korman
University Hospitals Cleveland Medical Center

Enoch Bortey
Trevi Therapeutics

Thomas R Sciascia
Trevi Therapeutics

Keywords

prurigo nodularis, nalbuphine, pruritus, clinical trial

Abstract

N/A

References

1. Elmariah S et al. J Am Acad Dermatol. 2021;84(3):747-760

2. Prurigo Nodularis – Market Insights, Epidemiology, and Market Forecast. Accessed September 14, 2022. https://www.delveinsight.com/report-store/prurigo-nodularis-market

3. Steinke S et al. J Am Acad Dermatol. 2018;79(3):457-463

4. Elmariah S et al. J Am Acad Dermatol. 2021;7:156-163

5. Kim BS et al. Abstract presented at: Winter Clinical Dermatology Conference–Hawaii®; January 16-24, 2021; virtual

6. Drug Enforcement Administration. Nalbuphine hydrochloride. Accessed September 14, 2022. https://www.deadiversion.usdoj.gov/drug_chem_info/nalbuphine.pdf

7. WHO Expert Committee on Drug Dependence. World Health Organ Tech Rep Ser. 1989;775:1-48

8. Weisshaar E et al. J Eur Acad Dermatol Venereol. 2021;36(3):453-461

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.103

Article Details

How to Cite
[1]
Ständer, S., Weisshaar, E., Parish, J.L., Szepietowski, J.C., Reich, A., Korman, N.J., Bortey, E. and Sciascia, T.R. 2022. Oral Nalbuphine Extended-Release Is Effective in Severe Prurigo Nodularis–Associated Pruritus: Results From a Phase 2b/3, Double-Blind, Placebo-Controlled Study. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s103. DOI:https://doi.org/10.25251/skin.6.supp.103.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Pruritus & Prurigo Nodularis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

<< < 1 2